INTRODUCTION
Bladder cancer has variable metastatic potential and almost any organ can be involved by metastasis. Lymph nodes, liver, lung, and bone are the most common metastatic sites of urothelial carcinoma of the bladder. Cutaneous and subcutaneous metastases are extremely rare associated with poor prognosis. It occurs most commonly in the locoregional area and via lymphatic drainage. Skin metastasis of bladder carcinoma can present as nodular, inflammatory, and fibrotic type [1] . Nodular metastases are common and may be of solitary or multiple type [2] . In this case report, we present a patient with an urothelial carcinoma of the bladder who developed cutaneous nodular metastases 2 months after the diagnosis.
II. CASE REPORT
A 72 year-old man underwent radical cystoprostatectomy with cutaneous uretero-ileostomy ad modum Bricker and pelvic lymphadenectomy 2 months previously for an urothelial carcinoma. The tumor had showed to be a conventional high grade urothelial carcinoma infiltrating muscularis propria, the adipose tissue around the bladder with lymphatic spread. Tumor invaded perivesical tissue macroscopically (pT3b), local metastasis were in two lymph nodes of 19 examined sized less than 2,5 centimeters in the greatest dimension (N2) and there were a prostatic adenocarcinoma with Gleason score 7. No other distant metastatic sites investigated by preoperative computed tomography scan and bone scintigraphy (M0) were found. In the first postoperative month erythematous nodular lesions appeared in the base of the chest region. Physical examination revealed many, rubbery and firm subcutaneous nodules located on the trunk in a variety of size ranging from 1 to 3 cm in diameter. The lesions were considered to be cutaneous metastasis of bladder urothelial carcinoma and chemotherapy with carboplatin and gemcitabine was started.
III. DISCUSSION
Urothelial carcinoma of the bladder is usually multifocal, frequently shows clinical relapses along the genitourinary tract [3] and it is characterized by immunohistochemical positivity for CK20, CK7, p63 and p53. [4] [5] The main primary sites for metastatic bladder carcinoma are liver, lung and bone. [1] Dermatological spread from primary genitourinary malignancies is very rare and occurs in 1% of patients with advanced disease. [1] Metastatic infiltration of the skin may be due to direct tumor invasion or hematogenous or lymphatic spread. It can also be a result of iatrogenic procedures, such as partial cystectomy, suprapubic cystotomy, pyelotomy and laparoscopy which are the most common causes of seeding of transitional cell carcinoma outside the urinary tract. [4] [5] Cutaneous metastases of bladder carcinoma are more commonly seen in male population. They rarely occur at the time of the diagnosis and they may clinically mimic many common dermatologic disorders. [3] However, it can be differentiated with skin biopsy. Immunohistochemically positive cytokeratin expressed from the uroepithelial tissue in skin biopsy can be useful in differential diagnosis. More than 90% of bladder carcinoma cases with cutaneous metastasis consist of transitional cell histopathology. [5] An unusual case of cutaneous metastasis from a papillary urothelial carcinoma of the urinary bladder DOI: 10.9790/0853-160305129131 www.iosrjournals.org 131 | Page
In our patient, cutaneous and liver (asymptomatic) metastasis occurred 2 months after the diagnosis of primary disease. Considering that up to 20% of patients with bladder cancer have lymphatic or vascular spread, primary skin metastasis is quite rare, as noted in our patient. [6] Similar to our case, Swick and Gordon [7] have reported a 69-year-old male with previously resected superficially invasive primary transitional cell carcinoma of the bladder who presented with distant cutaneous and central nervous system metastases associated with recurrent bladder cancer. The previous history of operated bladder tumor suggested the possibility of transitional cell carcinoma metastasis in our case. The topography of skin metastases is usually related to the site of primitive tumor, as a result of the lymphatic invasion; therefore the urothelial tumors often metastasize in genital area and low abdomen. [1] [2] Cutaneous metastases may morphologically resemble the primary tumor. However, they are often poorly differentiated, thus immunohistochemical investigation is often required to determine the primary origin. [1] [2] [3] [4] [5] [6] [7] In our case, the histological morphology of skin lesions was highly suggestive for secondary localization of cancer owing to the lack of involvement of the epidermis and its appendages, and to the widespread infiltration of the dermis with parallel arrangement of cords and nests suggestive of endo-lymphatic diffusion. The immunohistochemical study confirmed this hypothesis, since cells were positive for p63. The expression of CK7 has been recognized as a marker for cutaneous sweat gland tumours and it may be a useful marker of poorly differentiated glandular tumors. [8] P63 is a member of the p53 gene family and its expression may be an immunohistochemical marker for undifferentiated and poorly differentiated tumors of epithelial cell origin. This case makes dermatologists aware to consider skin metastases in differential diagnosis of non specific cutaneous lesions in patients with a history of primary visceral malignancy. The treatment of cutaneous metastases is a real challenge for clinicians. There are options of radiotherapy and chemotherapy for skin metastases. [1] [2] For single metastasis, combination of wide local surgical excision and systemic chemotherapy give satisfactory results in the control of skin disease. [9] The prognosis of patients with cutaneous spread of bladder cancer is generally poor and the median survival is less than 12 months. [10] 
IV. CONCLUSION
Despite treatment, cutaneous metastasis of bladder carcinoma is an indicator of poor prognosis; median diseasespecific survival is less than 6 months. Therefore, clinicians should recognize the importance of a thorough physical examination in patients with urothelial carcinoma. Skin biopsy should be performed for differential diagnosis and chemotherapy should be started considering that these patients have a poor prognosis if metastasis is found.
